


Product Name : IMU-838
Cat. No. : PC-49175
CAS No. : 717824-30-1
Molecular Formula : C₄₀H₃₄CaF₂N₂O₈
Molecular Weight : 748.793
Target : Other Targets
Solubility : 10 mM in DMSO



Biological Activity

Vidofludimus (IMU-838) is a selective and potent second-generation dihydroorotate dehydrogenase (DHODH) inhibitor with IC₅₀ of 160 nM, shows anti-SARS-CoV-2 activity with EC₅₀ of 7.6 uM in Vero cells.

Vidofludimus inhibits T cell proliferation with EC₅₀ of 11.8 uM, with a similar effect on CpG ODN 2006-PTO dependent B cell proliferation.

Vidofludimus is specific for human DHODH and does not have off-target effect on kinases, is about 7.5-fold and about 64.4-fold more active on human DHODH as compared to rat DHODH and mouse DHODH, respectively.

Vidofludimus inhibits specifically IL-17F, IL-17A and IFN-γ expression in PBMCs.

Vidofludimus is 2.6 times more potent in inhibiting DHO oxidation by human DHODH compared to teriflunomide (IC₅₀=420 nM).

Vidofludimus shows inhibition of rat EAE motor signs in a rat experimental autoimmune encephalomyelitis (EAE) model.

Vidofludimus exerts a broad-spectrum activity against a selection of major human pathogenic viruses.

References

Muehler A, et al. Mult Scler Relat Disord. 2020 Aug;43:102129.

Hahn F, et al. Viruses. 2020 Dec 5;12(12):1394.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com